- Home
- CRVO vs IMMX Comparison
CRVO vs IMMX Comparison
Compare CRVO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- IMMX
- Stock Information
- Founded
- CRVO 2001
- IMMX 2014
- Country
- CRVO United States
- IMMX United States
- Employees
- CRVO N/A
- IMMX N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CRVO Health Care
- IMMX Health Care
- Exchange
- CRVO Nasdaq
- IMMX Nasdaq
- Market Cap
- CRVO 67.4M
- IMMX 61.1M
- IPO Year
- CRVO N/A
- IMMX 2021
- Fundamental
- Price
- CRVO $6.96
- IMMX $2.65
- Analyst Decision
- CRVO Strong Buy
- IMMX Strong Buy
- Analyst Count
- CRVO 7
- IMMX 1
- Target Price
- CRVO $19.33
- IMMX $7.00
- AVG Volume (30 Days)
- CRVO 162.5K
- IMMX 137.1K
- Earning Date
- CRVO 08-08-2025
- IMMX 08-11-2025
- Dividend Yield
- CRVO N/A
- IMMX N/A
- EPS Growth
- CRVO N/A
- IMMX N/A
- EPS
- CRVO N/A
- IMMX N/A
- Revenue
- CRVO $9,308,215.00
- IMMX N/A
- Revenue This Year
- CRVO N/A
- IMMX N/A
- Revenue Next Year
- CRVO N/A
- IMMX N/A
- P/E Ratio
- CRVO N/A
- IMMX N/A
- Revenue Growth
- CRVO 15.14
- IMMX N/A
- 52 Week Low
- CRVO $1.80
- IMMX $1.26
- 52 Week High
- CRVO $20.63
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- CRVO 51.63
- IMMX 61.44
- Support Level
- CRVO $5.45
- IMMX $2.16
- Resistance Level
- CRVO $7.55
- IMMX $2.80
- Average True Range (ATR)
- CRVO 0.59
- IMMX 0.17
- MACD
- CRVO 0.14
- IMMX 0.04
- Stochastic Oscillator
- CRVO 75.71
- IMMX 80.00
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.